Showing 921 - 940 results of 3,158 for search 'Patient Number 9', query time: 0.13s Refine Results
  1. 921
  2. 922

    Risk factors associated with poor pain outcomes following primary knee replacement surgery: Analysis of data from the clinical practice research datalink, hospital episode statisti... by Hasan Raza Mohammad, Rachael Gooberman-Hill, Antonella Delmestri, John Broomfield, Rita Patel, Joerg Huber, Cesar Garriga, Christopher Eccleston, Rafael Pinedo-Villanueva, Tamer T Malak, Nigel Arden, Andrew Price, Vikki Wylde, Tim J Peters, Ashley W Blom, Andrew Judge

    Published 2021-01-01
    “…<h4>Conclusions</h4>We quantified the relative importance of individual risk factors including mild pre-operative pain, smoking, deprivation, obesity and opioid use in terms of the absolute proportions of patients achieving poor pain outcomes. These findings will support development of interventions to reduce the numbers of patients who have poor pain outcomes.…”
    Get full text
    Article
  3. 923
  4. 924
  5. 925

    Practice on Metered Dose Inhaler Techniques and Its Associated Factors among Asthmatic Patients at Debre Markos Comprehensive Specialized Hospital, East Gojjam, Ethiopia: A Prospec... by Tadele Asmare, Anteneh Belayneh, Bekalu Dessie

    Published 2021-01-01
    “…Results are presented in tables, figures, numbers, and percentages. Result. A total of 166 patients had involved in the study, of which 52.4% were females. …”
    Get full text
    Article
  6. 926

    Effect of oxytocin nasal spray pretreatment on postoperative acute stress disorder in patients with accidental traumatic fracture: a single-centre prospective randomised controlled... by Ling Ren, Qingqing Huang, Hengdi Zhang, Jingzheng Zeng, Yi Wen, Haifeng Shu, Gu Gong

    Published 2025-01-01
    “…Participants will be randomly categorised into two groups: a control group (0.9% normal saline nasal spray, 1 mL) and an oxytocin group (oxytocin nasal spray, 1 mL/40 IU) at a ratio of 1:1 using the random number table method. …”
    Get full text
    Article
  7. 927

    Prospective and Longitudinal Analysis of Lymphocyte Subpopulations in SARS-CoV-2 Positive and Negative Pneumonia: Potential Role of Decreased Naïve CD8<sup>+</sup> in COVID-19 Pati... by Makhabbat Bekbossynova, Lyudmila Akhmaltdinova, Kuanysh Dossybayeva, Ainur Tauekelova, Zauresh Smagulova, Tatyana Tsechoeva, Gulsimzhan Turebayeva, Aliya Sailybayeva, Zhanar Kalila, Takhmina Mirashirova, Timur Muratov, Dimitri Poddighe

    Published 2024-12-01
    “…Notably, this aspect was maintained during the follow-up period for at least 9 months. <b>Conclusions</b>: COVID-19 pneumonia seems to be associated with a lower number of naïve CD8<sup>+</sup> T cells compared to pneumonia patients negative for this virus. …”
    Get full text
    Article
  8. 928
  9. 929

    A phase Ia study of a novel anti-HER2 antibody–drug conjugate GQ1001 in patients with previously treated HER2 positive advanced solid tumors by Chenfei Zhou, Bin Wang, Christina Teng, Hui Yang, Sarina A. Piha-Paul, Gary Richardson, Ashanya Malalasekera, Yajun Sun, Wei Wang, Jieqiong Liu, Yan Shi, Xianbao Zhan, Charlotte Lemech

    Published 2025-01-01
    “…Results A total of 32 patients were enrolled, predominantly in breast (9), gastric or gastro-esophageal junction (9) and salivary gland cancer (4). …”
    Get full text
    Article
  10. 930

    The value of revascularization and adherence to therapy in the development of cardiovascular complications in long-term monitoring of patients with myocardial infarction of the rig... by V.Y. Tseluyko, T.A. Lozova, V.P. Zheleznyy, O.S. Sasyuk

    Published 2016-03-01
    “…The 1st group included 68 (43.9 %) patients who underwent surgical treatment, 87 (56.1 %) patients under conservative strategy composed the 2nd group. …”
    Get full text
    Article
  11. 931

    Beating-Heart Coronary Artery Bypass grafting (BH-CABG) in patients with End-Stage Renal Disease (ESRD): comparison of the Society of Thoracic Surgeons (STS) predicted risk with ac... by Louis Samuels, Anastasia Arce, Samiat Agunbiade, Suzanne Raws, Afshin Parsikia

    Published 2025-01-01
    “…Prolonged Lengths of Stay occurred in 3 patients (5.5%) compared to a predicted 16.9%. One-year mortality occurred in 8 patients (14.5%). …”
    Get full text
    Article
  12. 932

    Clinical outcomes of chimeric antigen receptor T-cell therapy following autologous hematopoietic stem cell transplantation in 38 patients with refractory/relapsed primary or second... by Jiaying Wu, Wanying Liu, Yang Cao, Yang Yang, Zhen Shang, Mi Zhou, Yicheng Zhang, Fankai Meng, Xiaojian Zhu, Yi Xiao

    Published 2024-11-01
    “…After therapy, the best overall response rate (ORR) of all patients was 78.9%. Subgroup analysis found that a lower ORR was observed in patients with lactate dehydrogenase levels above the upper limit of normal (60.0% vs. 91.3%, P = 0.039). …”
    Get full text
    Article
  13. 933
  14. 934
  15. 935
  16. 936
  17. 937

    Safety and efficacy of selective RIPK1 inhibitor SIR1-365 in hospitalized patients with severe COVID-19: A multicenter, randomized, double-blind, phase 1b trial by Norberto Chavez-Tapia, Muneeba Ahsan Sayeed, Shobha Luxmi, Douglas J. Kasper, Fenchao Xue, Yang Shen, Weiliang Fan, Wei Yuan, Bin Du

    Published 2025-01-01
    “…Compare to placebo, SIR1-365 significantly increased arterial oxygenation from baseline to day 7 (least-squares mean change [standard error]: 109.4 [26.4] vs. -24.2 [23.6]; P=0.0095), significantly reduced hospitalization duration after treatment (mean±standard deviation: [4.7±3.7] days vs. [8.6±5.6] days; P=0.0145) and respiratory failure incidence (8.3% vs. 38.1%; two-sided P=0.0291) during the study, and numerically shortened the time to clinical improvement in World Health Organization ordinal scale (median: 5.0 days vs. 9.0 days, P=0.0766). Conclusions: SIR1-365 was well tolerated and demonstrated a trend toward quicker recovery than placebo in hospitalized patients with severe COVID-19.Trial Registration ClinicalTrials.gov number: NCT04622332…”
    Get full text
    Article
  18. 938
  19. 939

    Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in pat... by Christy Ralph, Sumati Gupta, Matthew Zibelman, Brendan D Curti, Kevin J Harrington, Steven J O'Day, Andrew G Hill, David C Campbell, Gavin M Wright, David E Gerber, Jonathan E Rosenberg, Jaime R Merchan, Charles M Rudin, Hardev S Pandha, Wallace L Akerley, Daphne Day, Timothy D Clay, Ross R Jennens, Yixin Ren, Emmett V Schmidt, Lisa Guttman

    Published 2023-01-01
    “…This phase 1 study evaluated intravenous V937±pembrolizumab in patients with advanced solid tumors.Methods Patients had advanced non-small cell lung cancer (NSCLC), urothelial cancer, metastatic castration-resistant prostate cancer, or melanoma in part A (V937 monotherapy), and metastatic NSCLC or urothelial cancer in part B (V937+pembrolizumab). …”
    Get full text
    Article
  20. 940